RF Acquisition Corp II (RFAI) Company Overview

What does RF Acquisition Corp II do?

RF Acquisition Corp II, trading on Nasdaq under the ordinary-share symbol RFAI, is a special purpose acquisition company rather than an operating enterprise. It was incorporated in the Cayman Islands in February 2024 to raise capital, place most of that capital in a trust account, identify a private business, and complete a merger or similar transaction. The company’s latest Form 10-Q for the quarter ended March 31, 2026 still classifies it as a shell company with no operating revenue.

A listed pool of capital, not a conventional business

The central analytical point is that RFAI does not sell products, serve customers, employ a normal revenue model, or report operating segments. Its economic purpose is transactional. Public investors hold shares that are generally redeemable for their pro rata portion of the trust account before a business combination, while the sponsor and founders hold non-redeemable securities whose value depends much more heavily on a deal closing. That split creates very different incentives from those found in an established public company.

The intended strategic focus

The company said it intended to focus on Asian deep-technology businesses, including artificial intelligence, quantum computing, and biotechnology, although it retained broad legal flexibility. That search mandate became concrete in October 2025 when RFAI signed a business combination agreement with Singapore-based Nanyang Biologics. The proposed transaction would place Nanyang under a new holding company, NYB Holdings Limited, and the combined group is expected to use the reserved ticker NYB if the transaction closes.

How does RF Acquisition Corp II make money?

Before closing a merger, RFAI’s reported income does not come from commercial operations. It comes primarily from interest earned on securities or cash held in the trust account. In the first quarter of 2026, the trust generated $454,296 of interest income. That amount exceeded $360,594 of general, administrative, and operating costs, producing net income of $93,702. This is accounting profitability, but it should not be confused with a scalable business model.

Trust interest funds reported earnings

The real economic outcome depends on the merger

For public shareholders, the pre-deal return is driven mainly by the trust value, the market price relative to redemption value, transaction timing, and the possibility of receiving securities in the post-merger company. For the sponsor, economics are more asymmetric because founder shares and private securities can become valuable if a combination closes but may expire worthless if RFAI liquidates. Therefore, the primary “revenue engine” is not a product franchise; it is the conversion of a temporary listed vehicle into ownership of an operating target.

What does the latest quarter show?

The March 2026 quarter shows a vehicle that still had substantial protected trust assets but very little unrestricted cash. Total assets were $53.13 million, of which $52.89 million sat in the trust account. Cash outside the trust was only $34,737, down from $337,383 at December 31, 2025. This distinction is crucial: trust funds are largely reserved for redemptions or a transaction and generally cannot be used like normal corporate cash.

Liquidity outside the trust is the pressure point

The company used $267,646 of cash in operating activities during Q1 2026 and invested another $180,000 into the trust account, partly offset by $145,000 of financing inflows. These financing inflows included $25,000 of sponsor advances and $120,000 related to extension deposits. The result was a $302,646 decline in unrestricted cash during the quarter. That pattern means the sponsor and related parties remain important sources of bridge funding while the transaction process continues.

Net income does not equal free cash flow

RFAI reported positive net income because trust interest is recognized in earnings, yet it consumed cash in operations because that interest remained inside the trust. For analytical purposes, free cash flow before a merger is better approximated by unrestricted operating cash burn than by net income. The company’s cash-flow statement therefore gives a more useful picture than its earnings per share of $0.01 for Q1 2026.

How did the Nanyang Biologics transaction reshape the story?

The most important turning point occurred on October 2, 2025, when RFAI entered into a business combination agreement with Nanyang Biologics, NYB Holdings Limited, and an amalgamation subsidiary. Under the structure described in the October 2025 Form 8-K, RFAI would merge into NYB Holdings, and Nanyang would become a wholly owned operating subsidiary of the new public parent.

1. February 2024
   RF Acquisition Corp II was formed as a Cayman Islands blank-check company, creating the legal vehicle for a future transaction.
2. May 2024
   The company completed its initial public offering, raising gross proceeds of $115.0 million from 11.5 million units and placing the transaction capital into trust.
3. July 2024
   Ordinary shares and rights began separate trading under RFAI and RFAIR, making the capital structure more transparent to public investors.
4. June 2025
   Shareholder redemptions materially reduced the trust and the public-share count, increasing the importance of financing certainty.
5. October 2025
   RFAI signed the Nanyang Biologics combination agreement, shifting the thesis from target search to transaction execution.
6. March 2026
   NYB Holdings filed a public Form F-4 registration statement, moving the deal into the SEC disclosure and shareholder-approval phase.

What shareholders are being asked to underwrite

Nanyang describes itself as an AI-enabled biotechnology company focused on drug discovery. The transaction announcement referenced a pre-money equity valuation of approximately $1.5 billion, subject to the detailed terms, adjustments, approvals, and financing conditions in the definitive documents. RFAI shareholders therefore face a fundamental transition: before closing, the security behaves largely like a claim on trust value; after closing, it would become exposure to a high-risk, research-driven biotechnology enterprise.

What is the capital structure and redemption math?

At March 31, 2026, 4,831,265 ordinary shares were subject to possible redemption at $10.95 per share, representing $52.89 million in the trust account. An additional 3,512,500 ordinary shares were outstanding outside the redemption classification. The company also issued rights in its IPO structure, with each right entitling its holder to receive one-twentieth of one ordinary share upon completion of the initial business combination.

Why redemptions matter more than headline IPO proceeds

RFAI originally sold 11.5 million public units. By March 2026, only 4.83 million public shares remained subject to redemption, meaning a large portion of the original public capital had already been returned to investors. The trust balance consequently fell from its initial scale to $52.89 million. A transaction described using a $1.5 billion target valuation cannot be financed by the remaining trust alone; closing economics depend on the final redemption level, any PIPE or other financing, rollover equity, transaction costs, and the exact capitalization of NYB Holdings.

The deferred underwriting fee and sponsor financing

RFAI carried a $4.025 million deferred underwriting fee payable at March 31, 2026. It also owed $250,725 to the sponsor and recorded a $138,550 advance from a related party. These amounts are small relative to trust assets but significant relative to unrestricted cash of $34,737. They demonstrate why a SPAC can appear well funded on a total-assets basis while still relying on sponsor support for day-to-day bills.

Who owns and controls RF Acquisition Corp II?

RFAI has the classic SPAC governance split between redeemable public investors and a sponsor-led control group. Public shareholders provide trust capital and retain redemption rights. The sponsor holds founder shares and related securities that create strong incentives to complete a transaction. The company’s board and executive team, led by Chief Executive Officer and Chairman Tse Meng Ng and Chief Financial Officer Chee Soon Tham, oversee the merger process, regulatory filings, and extensions.

Economic ownership and voting influence are not the same

A public investor may hold a large portion of the remaining redeemable float yet still choose to redeem and vote according to the governing documents. Sponsor holders, by contrast, usually waive redemption rights on founder securities and are economically motivated to support the proposed transaction. This means raw share counts do not fully explain influence. The key governance questions are who can approve the combination, who is locked up after closing, and how much dilution arises from founder shares, rights, financing securities, and target rollover equity.

Governance after closing will be a new system

If the merger closes, RFAI itself will cease to be the public parent. NYB Holdings will survive, Nanyang will become its operating subsidiary, and the board, ownership mix, voting arrangements, and executive compensation system will follow the final transaction documents rather than RFAI’s current shell-company framework. Researchers should therefore use the NYB Holdings Form F-4 as the principal source for post-combination governance and dilution analysis.

What gives RFAI an advantage, and who are its competitors?

A SPAC’s competitive advantage does not come from patents, scale economies, or recurring customer relationships. It comes from sponsor reputation, sourcing access, transaction expertise, speed, and the ability to provide a credible path to a public listing. RFAI’s stated Asian deep-tech focus and Singapore base may help it evaluate companies that are less visible to U.S.-centric sponsors. Its management team also completed the target search within roughly eighteen months of formation, which suggests relevant sourcing access.

The real competitors are alternative financing routes

RFAI competes with other SPACs, private-equity sponsors, venture investors, strategic acquirers, crossover funds, and traditional IPO banks. For Nanyang, the relevant comparison is not simply another blank-check company. It is every alternative way to fund development while achieving liquidity and public-market access. In that contest, RFAI’s remaining trust capital is modest, so certainty of financing and transaction execution matter more than the original $115.0 million IPO headline.

Why the moat is temporary

Any advantage is transaction-specific and expires if the combination fails. RFAI has no recurring revenue, proprietary operating assets, or customer lock-in. Its value proposition exists only while it can deliver shareholder approval, sufficient cash, an effective registration statement, Nasdaq eligibility, and a completed merger. That makes the “moat” procedural rather than durable.

Which KPIs matter most for RFAI?

Traditional ratios such as revenue growth, gross margin, and return on invested capital are not meaningful before the merger because RFAI has no operating business. The useful indicators instead measure trust protection, redemptions, cash burn, transaction progress, and dilution. These metrics show whether the vehicle can reach closing with enough capital and an acceptable post-deal share structure.

A practical SPAC valuation formula

Before closing, the rough analytical anchor is trust value per share minus expected time, transaction, and failure risk, plus any value assigned to the embedded right or potential post-merger upside. After closing, that anchor disappears. Valuation then depends on NYB Holdings’ fully diluted equity value, net cash, development pipeline, probability-adjusted drug economics, operating expenses, capital needs, and time to commercialization.

What risks could change the outcome?

The dominant risk is that the proposed combination does not close. Conditions include regulatory effectiveness, shareholder approval, compliance with listing standards, satisfaction of transaction covenants, and sufficient financing. Failure could lead to another target search, further extensions, more cash burn, or liquidation. The company’s latest filing also emphasizes its limited operating history, shell-company status, and dependence on completing a business combination within the permitted period.

The target adds a different risk profile

Nanyang’s biotechnology model introduces scientific, regulatory, intellectual-property, data-validation, and financing risks that are absent from the current shell. AI-enabled drug discovery can improve target identification and screening efficiency, but it does not eliminate clinical failure, long development timelines, manufacturing complexity, or the need for regulatory approval. Investors should not treat the “AI” label as a substitute for program-level evidence.

Conflicts of interest are structural

Sponsor securities can lose substantially all value if no deal closes, while public investors can redeem. This asymmetry may encourage completion of a transaction that is better than liquidation for the sponsor but not necessarily optimal for every public holder. The appropriate safeguard is careful review of the merger documents, fairness disclosures, financing terms, lockups, and pro forma ownership—not reliance on headline valuation.

Why does RFAI matter for valuation?

RFAI requires two different valuation frameworks separated by the closing date. Before the deal, it resembles a cash-backed event security. The key inputs are trust value, redemption mechanics, time to vote, interest accrual, liquidation probability, and market liquidity. After the deal, it would become a biotechnology equity whose worth depends on scientific assets, capital requirements, and probability-adjusted future cash flows.

DCF inputs after closing

A conventional revenue-based DCF may be unsuitable if Nanyang remains pre-commercial. A probability-adjusted net present value approach would separate each development program, estimate addressable population, pricing, launch timing, peak penetration, operating margin, taxes, reinvestment, and probability of technical and regulatory success. Corporate expenses, platform spending, future fundraising, and share dilution must be added explicitly. A long-duration biotech model is highly sensitive to discount rates and terminal assumptions.

Comparable-company analysis also needs discipline

The most relevant comparables would be AI-enabled drug-discovery platforms and development-stage biotechnology companies at similar pipeline maturity, not mature pharmaceutical companies with approved products. Enterprise value, cash runway, partnerships, milestone economics, clinical-stage assets, and platform validation matter more than revenue multiples when revenue is limited or absent. The announced transaction valuation is therefore a starting point for analysis, not proof of fair value.

What should students and investors monitor next?

The next phase is dominated by transaction milestones rather than quarterly earnings growth. The public registration statement, subsequent amendments, and any new official transaction announcement will determine whether the proposal advances, changes, or terminates.

What is the key takeaway from RF Acquisition Corp II analysis?

RF Acquisition Corp II is best understood as a bridge between a protected trust account and a proposed biotechnology listing. At March 31, 2026, the company held $52.89 million in trust, had 4.83 million redeemable shares worth $10.95 each, and remained a shell with no operating revenue. Its positive Q1 2026 net income of $93,702 came from trust interest, while unrestricted operations consumed $267,646 of cash and left only $34,737 outside the trust.

The Nanyang Biologics agreement gives the vehicle a clear strategic purpose, but it also replaces a relatively simple trust-value analysis with a much more demanding biotechnology valuation problem. The announced approximately $1.5 billion pre-money valuation, the final redemption level, new financing, rights conversion, founder economics, and post-close pipeline disclosures will determine how much operating value each public share ultimately represents.